Reviewing Cidara Therapeutics (CDTX) and Its Rivals
Cidara Therapeutics (NASDAQ: CDTX) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Cidara Therapeutics to related businesses based on the strength of its profitability, risk, earnings, valuation, analyst recommendations, institutional ownership and dividends.
Valuation & Earnings
This table compares Cidara Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cidara Therapeutics||N/A||-$48.16 million||-2.28|
|Cidara Therapeutics Competitors||$284.28 million||$34.29 million||134.32|
This table compares Cidara Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cidara Therapeutics Competitors||-5,302.67%||-356.18%||-38.99%|
Insider & Institutional Ownership
55.5% of Cidara Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 18.9% of Cidara Therapeutics shares are owned by insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a breakdown of current ratings and recommmendations for Cidara Therapeutics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cidara Therapeutics Competitors||846||3197||11593||230||2.71|
Cidara Therapeutics currently has a consensus target price of $13.85, suggesting a potential upside of 78.71%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.91%. Given Cidara Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Cidara Therapeutics is more favorable than its peers.
Volatility and Risk
Cidara Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500. Comparatively, Cidara Therapeutics’ peers have a beta of 6.01, meaning that their average share price is 501% more volatile than the S&P 500.
Cidara Therapeutics beats its peers on 8 of the 12 factors compared.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. The Company is also developing CD201, its bispecific antimicrobial immunotherapy.
Receive News & Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.